VerastemVSTM
Recorded

Verastem 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration54 minParticipants16

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon, and welcome to Verastem Oncology's third quarter 2026 earnings conference call. My name is Didi, and I will be your call operator today. Please note, this event is being recorded. All participants will be in a listen-only mode. After today's presentation, there will be an opportunity to ask questions. I will now turn the call over to Julissa Viana, Senior Vice President of Corporate Communications, Investor Relations, and Patient Advocacy at Verastem Oncology. Please go ahead. Thank you, operator.

Julissa VianaSVP of Corporate Communications, Investor Relations, and Patient Advocacy

Welcome, everyone, and thank you for joining us today to discuss Verastem's third quarter 2026 financial results and recent business updates. This afternoon, we issued a press release detailing these results, along with the slide presentation that we will reference during our call today. Both are available on the Investor Relations section of our website. Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. We encourage you to consult the risk factors discussed in our SEC filings for additional detail. Additionally, today, we will be discussing certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are provided in the press release we issued today.

Julissa VianaSVP of Corporate Communications, Investor Relations, and Patient Advocacy

Joining me on today's call to deliver prepared remarks and take your questions are Dan Paterson, President and Chief Executive Officer, Dan Lyons, Chief Commercial Officer, and Dr. Michael D. Kauffman, President of Development, and lastly, Dan Calkins, Chief Financial Officer. I will now turn the call over to Dan.

Dan PatersonPresident and CEO

Thank you, Julissa. Good afternoon, and thank you for joining our call today. We are encouraged by the progress we have made across our commercial business and the VS-7375 development program. We generated net product revenue of $24 million in the third quarter, with demand holding steady for AVMAPKI/FAKZYNJA CO-PACK, and strong refills offsetting new patient starts after significant growth in Q2. As Dan Lyons will discuss, we feel that there is still considerable opportunity to be realized for the CO-PACK. While we continue to see a positive impact from the changes we have made throughout the commercial organization, we are making additional efforts to gather feedback from physicians to understand patient experiences and educate on new and existing initiatives. We are also excited to share that our new blister pack NDA has been accepted by the FDA with priority review and a PDUFA date of February 2027.

Dan PatersonPresident and CEO

This is an important step we are taking to further support patient convenience and adherence to the CO-PACK. Turning to the VS-7375 program, in October, we announced new clinical data from our TARGET-D 101 trial, including, for the first time, U.S. efficacy data and updated safety and tolerability results in KRAS G12D-mutated pancreatic, colorectal, and lung cancers. As Michael Kauffman will discuss in more detail, we set a new efficacy benchmark in pancreatic cancer with compelling and confirmed response rates across lines of therapy, and we demonstrated encouraging anti-tumor activity in both colorectal and non-small cell lung cancers. With longer follow-up, VS-7375 continued to demonstrate a favorable and manageable safety profile at both the 600 and 900 milligram dose level.

Dan PatersonPresident and CEO

Overall, we believe that VS-7375 has a potential best-in-class profile, and with the recent agreement with the FDA to start our first-line PDAC study, we have an opportunity to bring a chemo-free option to patients with pancreatic cancer. Building on these encouraging VS-7375 data, we further strengthened our balance sheet by raising gross proceeds of approximately $250 million in October. Together with our current cash position and expected revenues from the AVMAPKI/FAKZYNJA CO-PACK, the financing proceeds are expected to fund operations across our broad clinical development plans into the first half of 2028. This funding supports our opportunity to expedite the development pathway for VS-7375's phase II trial readouts and initiation of three phase III trials, including our phase III PDAC trial. We look forward to advancing parallel development paths in pancreatic, colorectal, and lung cancers, with multiple opportunities to create value along the way.

Dan PatersonPresident and CEO

Lastly, in October, we announced that I will be stepping down as President and CEO at the end of 2026, with Michael Bailey, current Verastem board member, stepping into the role. This transition follows my planned retirement, though I will continue serving on the company's board of directors and as an advisor. Michael is an accomplished biopharmaceutical executive and brings a wealth of experience in oncology drug development and commercialization experience. Most recently, Michael served as President and CEO of AVEO Pharmaceuticals, leading the organization to their acquisition by LG Chem, and subsequently led the integrated company through June of this year. Michael will be an important leader through Verastem's next phase of commercial growth, clinical advancement, and operational execution. I am extremely proud of all that we have accomplished in my 15 years at Verastem.

Dan PatersonPresident and CEO

Our work has benefited patients, physicians, families, and the broader healthcare system, and I have great confidence it will continue to make positive impact with our promising future ahead. With that, I will turn the call over to Dan Lyons for our commercial update.

Dan LyonsChief Commercial Officer

Dan? Thanks, Dan. In the third quarter, net product revenue for AVMAPKI/FAKZYNJA CO-PACK was $24 million.

Dan LyonsChief Commercial Officer

This revenue was driven by expanded prescribing across both community and academic accounts, with increasing refill rates throughout the quarter serving as the foundation of our performance. We also saw moderation in new patient starts after significant overall growth in the second quarter, reflecting seasonal headwinds in the late summer. Given the episodic nature of treatment persistence in rare diseases like low-grade serous ovarian cancer, new patient starts can fluctuate quarter to quarter. As we are in our first full year of the launch, we continue to see broader physician adoption and remain confident in our ability to grow the AVMAPKI/FAKZYNJA business as more physicians gain experience with the CO-PACK.

Dan LyonsChief Commercial Officer

As the launch matures, prescribers are increasingly choosing the CO-PACK at a patient's first or next recurrence, as appropriate LGSOC patients are prescribed their next treatment. We have shared before, we have seen physician-directed utilization outside of LGSOC, primarily in solid tumors such as pancreatic cancer. As a reminder, this is not an approved indication of the CO-PACK, and we do not promote its use in this setting. With the recent availability of allele-specific and pan-RAS clinical trials, as well as a recently approved RAS therapy in pancreatic cancer, we anticipate an impact on the business as the treatment patterns evolve. Importantly, our commercial strategy remains focused firmly on the approved indication in KRAS-mutated recurrent LGSOC and helping physicians identify appropriate patients and initiating CO-PACK therapy earlier in the course of recurrent disease.

Dan LyonsChief Commercial Officer

Our CO-PACK commercialization efforts remain centered around three priorities: driving consistent new patient demand, expanding use earlier in the treatment journey, and helping patients stay on therapy to realize the full benefit of treatment. Let's talk more about our progress with these efforts. First, we are prioritizing growth in new patient starts. While new patient starts moderated in the third quarter, we continue to see adoption broaden through the addition of first-time prescribers and new accounts across both academic and community settings. We continue to work closely with gynecologic oncologists, as they are the primary prescribers of the CO-PACK, and learn from their role in managing patients with LGSOC from diagnosis through the course of their disease. In the community setting, we continue to work with practices to identify patients through site-specific alerts and greater awareness around the disease and how to manage patients.

Dan LyonsChief Commercial Officer

Adoption in this market is influenced by both ongoing promotional engagement and physicians' experience with the treatment. Many of our community gynecologic oncologists may only see one to four patients with LGSOC per year, making education prior to prescribing and continued support as they gain experience especially important. Second, we are prioritizing initiatives to drive use in the right patients at the first or next recurrence. Throughout the third quarter, we continue to monitor several indicators that physicians are initiating treatment earlier. These observations are informed by our internal prescribing data, field insights, physician discussions, and market research. As we have discussed previously, the early launch included a meaningful proportion of patients who were heavily pre-treated and further along in their disease. As we see treatment duration increase as the launch matures, we are confident the initiatives are working.

Dan LyonsChief Commercial Officer

Third, we are focused on helping patients to stay on the CO-PACK longer and making the treatment experience as simple as possible. Refills were a key contributor to third-quarter revenue, and strong refill rates tell us that our efforts to support patients in remaining on therapy are gaining traction. As prescribers gain experience with the CO-PACK, they are becoming more confident in proactively managing adverse events and helping patients remain on treatment. Patients who successfully navigate the early cycles of therapy tend to stay on treatment longer, creating a growing base of refill demand. Building on that momentum, we are focused on further improving the patient experience through our new AVMAPKI tablet formulation and blister pack presentation of both AVMAPKI and FAKZYNJA. As Dan mentioned, the NDA has been accepted by the FDA with priority review and a February 2027 PDUFA date.

Dan LyonsChief Commercial Officer

If approved, the new formulation would replace the four 0.8 milligram AVMAPKI capsules taken per dose with a single tablet, meaningfully reducing pill burden. The new blister pack presentation would also make it easier for patients to track and manage their medication, including dedicated packaging for reduced dosing, while eliminating the current refrigeration requirement and making the CO-PACK easier to store and travel with. Taken together, we believe these enhancements can simplify the day-to-day treatment experience, support adherence and consistent refills, and ultimately help patients stay on therapy longer. Importantly, these proposed changes do not change the approved indication, efficacy, or safety profile of the CO-PACK. In closing, we remain confident in our ability to capture the significant opportunity that remains in KRAS-mutated recurrent LGSOC.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day